Syndecan-1 (CD138) immunohistochemical expression patterns in lupus nephritis; reflections on different clinicopathological parameters

Marwa M Shakweer, Lobna S Shash

Department of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

**ARTICLE INFO**

**Article type:** Original Article

**Article history:**
Received: 7 February 2020
Accepted: 10 May 2020
Published online: 29 May 2020

**Keywords:** Syndecan CD138 Immunohistochemistry Lupus nephritis ISN/RPS classification NIH activity index NIH chronicity index

**ABSTRACT**

**Introduction:** Syndecan 1 (SCD1) is a lectin expressed at the surface of renal tubular epithelial cells and plasma cells. In epithelial cells, cell surface syndecan1 is cleaved by inflammation-induced proteases (e.g., ADAMTS, MMP), since loss of cell surface syndecan1 is associated with higher susceptibility to cell damage.

**Objectives:** To explore a potential additional value of SCD1 immunohistochemical expression in lupus nephritis specimens of different ISN/RPS classes and NIH activity and chronicity indices.

**Patients and Methods:** This retrospective study included 50 renal biopsy specimens diagnosed as lupus nephritis at the pathology laboratory, and electron microscopy (EM) laboratory of Ain-Shams University specialized hospitals. Data were collected from records as personal data, medical history and laboratory results including serum creatinine and proteinuria. Immunohistochemical expression of syndecan-1 was evaluated in renal tubular epithelial cells (TECs) followed by correlation with different clinicopathological parameters.

**Results:** Fifty renal biopsy specimens with lupus nephritis including 14 cases of class II, 4 cases of class III, 20 cases of class IV and 12 cases of class V were re-evaluated. The mean serum creatinine was 1.57 ± 0.67 mg/dL. Nine cases (18%) were negative for proteinuria, while 41 cases (82%) were presented with proteinuria with a mean of 1.5 ± 0.9 g/24 h. There was no statically significant difference in the percentage of SCD-1 expression with different lupus classes. Serum creatinine and albumin showed a statistically significantly different correlation with semiquantitative score of SCD-1 expression. The highest value of creatinine detected with score 1 of SCD-1 expression (P = 0.038) and the highest value of urinary albumin was recorded with score 1 of SCD-1 expression. Accordingly, the lowest mean of urinary albumin recorded in SCD-1 score 3 (P < 0.001). There was a weekly negative association between loss of SCD-1 expression and increased NIH activity and chronicity indices.

**Conclusion:** Loss of syndecan immunohistochemical expression in renal TECs in lupus nephritis is highly associated with proteinuria and elevated serum creatinine and can be used as a predictive marker for disease severity and progression.
stage renal disease (ESRD). These studies reported a strong association between low glomerular filtration rate (GFR), high chronicity indices and poor renal outcome (6-11). Tubulointerstitial lesions in the form of interstitial inflammation and fibrosis, and tubular atrophy were known as one of the prognostic markers in lupus nephritis (12). Several underlying mechanisms for tubulointerstitial lesions include proteinuria, immune complex deposition in the interstitium, and rupture of the Bowman’s capsule and induction of pro-inflammatory molecules at the surface of renal tubular cells (13-15).

Previous studies showed that changes in heparan sulfate proteoglycans (HSPGs) affect renal inflammatory responses as observed in experimental renal IRI (ischemia-reperfusion injury) and primary human kidney disease (16,17). HSPGs were proved to be involved in angiogenesis, wound healing, tumor progression and inflammation through binding and presenting growth factors, chemokines and cytokines, as well as facilitating inflammatory cells adhesion by binding to the leukocyte adhesion molecule L-selectin (16,18-22).

Syndecan-1 (SCD1) is a transmembrane HSPG involved in epithelial differentiation and re-epithelialization during wound healing and inflammation (18,23-25). There are four members of syndecans. SCD1, known as CD138, is expressed on the surface of plasma, endothelial and epithelial cells (18). During tissue injury, the SCD1 shedding is accelerated through the release of different proteases and growth factors, thus it can be detected in inflammatory fluids. Epithelial cell surface SCD1 is cleaved by inflammation-induced proteases (ADAMTS and MMP) (26).

Additionally, shed/desquamated soluble syndecan-1 was found in sepsis (27), graft versus host disease (28), multiple myeloma and acute myeloid leukemia (29,30).

Few studies have assessed the role of serum SCD1 in lupus nephritis. Serum syndecan-1 was found to be significantly high in active lupus nephritis patients and correlated with disease activity. It was also significantly related to the presence of musculoskeletal manifestations and serositis which give a promising role in prediction of disease activity (31,32). Moreover, loss of cell surface SCD1 is associated with higher susceptibility to cell damage, in gastroenterological and renal disorders, and it has been recently identified as a marker of renal tubular stress (33-36).

To date, SCD1 expression in lupus nephritis has scarcely been studied. Even in these few studies, the focus was directed on its expression in plasma cells regardless of its assessment in renal tubular epithelial cells (TECs). In these studies, SCD1 stained plasma cells were not seen in glomeruli even in proliferative glomerulonephritis and they were mostly seen as scattered single cells in the interstitium of the cortex and outer medulla. Additionally, the average medullary plasma cell SCD1 expression was found to be associated with higher disease activity and chronicity as well as all lupus nephritis classes except class II (37).

Accordingly, the study by Pamfil et al (36) showed the link between renal TEC damage (indicated by lost SCD1 expression) and poorer renal outcome in LN, which was assessed by lower GFR (36). Therefore, we sought to explore the patterns of SCD1 TEC expression in lupus nephritis patients and test potential reflections of such patterns on the prognostic indices of lupus nephritis. The role played by SCD1 in inflammation/re-epithelialization sequel has given us insights to test its expression in TEC in lupus nephritis patients to find if there is a link with different clinicopathologic parameters.

Objectives
The aim of the present study is to evaluate SCD1 immunohistochemical expression in renal TECs in lupus nephritis in correlation with various clinicopathological parameters.

Patients and Methods

Study population
This retrospective study included 50 renal biopsy specimens diagnosed as lupus nephritis at the pathology laboratory, and electron microscopy (EM) laboratory of Ain-Shams University specialized hospitals. Data were collected from records as personal data, medical history and laboratory results including serum creatinine and proteinuria. Cases with adequate paraffin tissue blocks for immunostaining were enrolled in the study. All renal biopsy specimens were graded according to the 2003 international society of nephrology/renal pathology society (ISN/RPS) classification system (38) and national institutes of health (NIH) activity and chronicity indices (39,40). The renal specimens were re-evaluated by light microscopy (LM) and immunohistochemical staining using (syndecan-1).

Light microscopy
Formalin-fixed, paraffin-embedded tissues from all cases were retrieved from the archive of the pathology laboratory. Slides were re-evaluated by two pathologists using LM (Olympus BX31) according to the histopathological guidelines for the evaluation and scoring of lupus nephritis (38-40). The pathologists were blinded to the clinical parameters of the patients.

Immunohistochemical staining method
Tissue sections were deparaffinized, rehydrated, and the endogenous peroxidase activity was quenched by
10-minute incubation in 3% hydrogen peroxide in methanol. After antigen retrieval and protein block, the primary antibody (mouse monoclonal anti-human syndecan-1 antibody; sc-390791, Santa Cruz) was supplied with dilution (1:50). The secondary antibody (supersensitive immunodetection system (Biogenex, catalog No: AD0000-SL) was then applied followed by peroxidase labeled streptavidin. Slides were incubated for 10 minutes with substrate chromogen (DAB) mixture. Finally, the slides were counterstained and mounted with Canada balsam.

Any staining detected in membranes of TECs is considered positive.

**Evaluation of immunostaining**

Two scoring methods for SCD-1 expression in renal tubular epithelium were used as follows:

(a) Quantitative score; by evaluation of the percentage of SCD-1 positive TECs to the whole area of renal cortical tubules in the examined specimen (typically 5–10 visual fields per biopsy) (41).

(b) Semiquantitative score;
   - Score 0; cortical renal tubules are negative for SCD-1
   - Score 1; positive membranous SCD-1 in <30% of renal cortical tubules
   - Score 2; positive membranous SCD-1 in 30-60% of renal cortical tubules
   - Score 3; positive membranous SCD-1 in >60% of renal cortical tubules

The intensity of immunostaining was graded into weak, moderate, strong.

**Ethical issues**

This investigation was in accordance with the Declaration of Helsinki. This investigation was conducted retrospectively on paraffin embedded blocks of kidney biopsies to test SCD-1 immunohistochemical expression in renal TECs. The study was approved by the ethical board committee of Faculty of Medicine, Ain Shams University.

**Statistical methods**

Data was revised for its completeness and consistency. Double data entry on SPSS program version 16 was done. Quantitative data were summarized by mean along with standard deviation while qualitative data were summarized by frequencies and percentages. Analysis of variance, chi-square test and Spearman’s correlation coefficient test were used for the analysis of significant differences or associations.

**Results**

Fifty renal biopsy specimens with lupus nephritis were re-evaluated including (14 cases of class II, 4 cases of class III, 20 cases of class IV and 12 cases of class V). Forty-two cases (84%) were females and eight (16%) were males, with mean age of 27.96 ± 12.9 years.

The mean serum creatinine was 1.57 ± 0.67 mg/dL. Nine cases (18%) were negative for proteinuria, while 41 cases (82%) were presented with proteinuria with a mean of 1.5 ± 0.9 g/24h.

NIH activity index was ranging from 1/24 to 18/24 with a mean value 6.24 ± 4.3. NIH chronicity index was ranging from 0/12 to 8/12 with a mean value 2.18/12 ± 2.22.

Regarding comparison of different variables based on ISN/ RPS class; no statistically significant difference in percentage of SCD-1 expression and the lupus classes was detected. We found a significantly higher mean age in class III (P=0.011). Moreover, serum creatinine showed a significant difference between groups, with the highest value in class IV, followed by class III (P<0.001). Accordingly, proteinuria showed a significant difference between groups, with the highest value in class V, and the lowest mean in class II (P<0.001; Table 1).

Serum creatinine and albumin showed a statistically significantly different correlation with semiquantitative score of SCD-1 expression based on percentage of stained cells, with the highest value of creatinine which was detected with score 1 of SCD-1 expression (P=0.038). Additionally, the highest value of urinary albumin was detected with score 1 of SCD-1 expression (Figures 1A and 1B), while the lowest mean of urinary albumin recorded in SCD-1 score 3 (P<0.001; Table 2; Figures 2A and 2B).

Regarding staining intensity, a statistically significant positive correlation between moderate intensity of SCD-1 expression and both serum creatinine (P=0.043), and urinary albumin (P<0.001) was found (Table 3; Figure 3).

Correlation between SCD-1 expression and NIH activity and chronicity indices was not significant. However a negative association between SCD-1 percentage and SCD-1 score and also intensity with increased NIH activity and chronicity indexes was noted, nonetheless, such association didn’t mount to statistical significance (Table 4).

**Discussion**

SCD-1 is one of the four transmembrane HSPGs of the syndecan’s family. All family members contain a transmembrane core protein to which glycosaminoglycan side chains are extracellularly attached (42). In adults, SCD-1 is mainly expressed by hepatocytes (43), epithelial cells (44) and plasma cells (45). The role of SCD-1 in re-epithelialization during wound healing and its role in restoration of TEC damage after ischemia reperfusion injury was established (18,23-25,41).
In the present work, evaluation of tissue SCD-1 immunohistochemical expression in renal TEC in lupus nephritis patients and its correlation with various clinicopathological parameters was our main concern.

We found a statistically significant inverse relationship between the loss of SCD-1 expression and increased proteinuria and serum creatinine. Our results were concordant with the study by Salam et al (32) who investigated the role of serum SCD-1 in lupus nephritis and revealed a significantly higher SCD-1 in patients with active lupus nephritis compared to those with extra-renal flare and inactive disease ($P<0.001$ and $P<0.001$ respectively). They found a highly statistically significant correlation between serum SCD-1 and 24h urinary proteinuria, decreased serum complement as well as SLEDAI (systemic lupus erythematosus disease activity...
Syndecan-1 (CD138) in lupus nephritis

In light of the previous data in the literature and the present study, we noted that both elevated serum SCD-1 and loss of tissue SCD-1 on TEC are related to progression of lupus nephritis. This inverse relationship between serum and tissue SCD-1 could be attributed to endothelial glycocalyx loss and/or shedding from the renal epithelium. During tissue injury, SCD-1 shedding is accelerated through the release of different proteases and growth factors, thus it can be detected in inflammatory fluids (26,44). Therefore, we recommend further studies investigating both serum and tissue SCD-1 expression.

Table 2. Creatinine and albumin level according to semiquantitative score of SCD-1 expression (ANOVA test)

| Semi-quantitative score of SCD-1 | N  | Mean | SD  | 95% CI for Mean | P  |
|-------------------------------|----|------|-----|-----------------|----|
|                               |    |      |     | Lower bound     |    |
|                               |    |      |     | Upper bound     |    |
| Creatinine                    |    |      |     |                  |    |
| 1                             | 1  | 25   | 1.81*| 0.78            | 1.48 | 2.13 |
| 2                             | 2  | 10   | 1.33b| 0.53            | 0.95 | 1.71 | 0.038*|
| 3                             | 3  | 15   | 1.33b| 0.35            | 1.14 | 1.53 |
| Albumin                       |    |      |     |                  |    |
| 1                             | 1  | 25   | 2.00*| 0.71            | 1.71 | 2.29 |
| 2                             | 2  | 10   | 1.40b| 0.97            | .71  | 2.09 | <0.001*|
| 3                             | 3  | 15   | 0.73b| 0.70            | .34  | 1.12 |

Significance level $P \leq 0.05$, *Significant, ns =non-significant.
Tukey’s post hoc test: Within the same comparison, means sharing the same superscript letter is not significantly different.

Table 3. Creatinine and albumin level according to intensity of SCD-1 staining (ANOVA test)

|                  | N  | Mean | SD  | 95% CI for Mean | P  |
|------------------|----|------|-----|-----------------|----|
|                  |    |      |     | Lower bound     |    |
|                  |    |      |     | Upper bound     |    |
| Creatinine       |    |      |     |                  |    |
| 0.00             | 0  | 2    | 1.20b| 0.28            | -1.34 | 3.74 | 0.043*|
| 1.00             | 1  | 8    | 1.46b| 0.49            | 1.06  | 1.87 |
| 2.00             | 2  | 16   | 1.95b| 0.79            | 1.53  | 2.37 |
| 3.00             | 3  | 24   | 1.38b| 0.56            | 1.15  | 1.62 |
| Albumin          |    |      |     |                  |    |
| 0.00             | 0  | 2    | 0.50b| 0.71            | -5.85 | 6.85 | 0.00*|
| 1.00             | 1  | 8    | 1.75b| 0.46            | 1.36  | 2.14 |
| 2.00             | 2  | 16   | 2.18b| 0.54            | 1.90  | 2.48 |
| 3.00             | 3  | 24   | 1.04b| 0.95            | 0.64  | 1.44 |

Significance level $P \leq 0.05$, *Significant, ns =non-significant.
Tukey’s post hoc test: Within the same comparison, means sharing the same superscript letter is not significantly different.
in TECs in patients with lupus nephritis to confirm this relationship and detect sensitivity of each procedure in prediction of disease activity. We also recommend investigating SCD-1 on desquamated/shed urinary TEC by flow cytometry in cases of lupus nephritis.

Supporting this hypothesis; Celie et al (41) investigated the pattern of SCD-1 expression in renal TEC in murine ischemia reperfusion injury and human renal allograft transplantation and found increased epithelial SCD-1 in allografts was correlated with low-proteinuria and serum creatinine, less interstitial inflammation, less tubular atrophy, and prolonged allograft survival. They hypothesized that SCD-1 is involved in tubular repair and survival upon renal transplantation and proposed it as a novel marker of renal allograft survival.

Additionally, Pamfil et al (36) found that SCD-1 immunohistochemical expression was significantly higher in biopsies where no tubular damage was evidenced at histological evaluation in cases of lupus nephritis.

In our study, a direct relation between tubular SCD-1 expression and different ISN/ RPS classes could not be detected. Classification of lupus nephritis classes varies according to site of immune complex deposition. Immune complexes deposit in the mesangium or the subendothelial and subepithelial spaces or in peritubular capillaries depending on the quality of the autoantibodies, the duration, and severity of lupus nephritis (47). This finding implies that immune complex formation in the mesangium causes class I and II lesions, subendothelial immune complex formation in class III and IV, and subepithelial immune complexes in class V (38). In the present work, we did not demonstrate SCD-1 expression in renal glomeruli in all classes, thus correlating a link between glomerular SCD-1 expression as a pathogenic factor determining the site of immune complex deposition couldn’t be established. From the fore-mentioned results, the role of TEC-SCD-1 involvement in disease progression was highlighted while its role in disease initiation needs to be further investigated in larger studies.

Conclusion
In this study we revealed a clear statistically significant predictive role of TEC-SCD-1 immunohistochemical expression as an adverse predictive marker of disease progression and tubular damage in lupus nephritis patients regardless of their class. Accordingly, we propose SCD-1 immunohistochemical testing as a helpful adjunct tool to histopathological evaluation in improving insightful tailored management plans.

Limitations of the study
The missed relationship between loss of SCD1 expression and different ISN/RPS classes could be attributed to the limited number of cases. Hence further studies with larger sample size may reach a statistically significant value and prove the role of SCD1 in the process of disease initiation.

Acknowledgments
We acknowledge our missed mentor Prof. Elham I Seif, former professor of pathology, Faculty of Medicine, Ain Shams University for supplying us with knowledge and experience in the field of nephropathology. We would like to thank Prof. Dalia El-Rouby, Professor of Oral Pathology, Faculty of Dentistry and Oral Medicine, Cairo University for helping us with her experience in the field of data management and basic statistics.

Authors’ contribution
MMS: designing the idea and study plan, data collection and writing the manuscript. LSS: follow up the staining procedures, scoring of immunohistochemistry and photographing, revising and editing the manuscript. Both the authors read, revised and approved the final manuscript.
Syndecan1- (CD138) in lupus nephritis

Conflicts of interest
The authors declare no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
No funding sources to disclose.

References
1. Hahn BH. Antibodies to DNA. N Engl J Med; 1998;338(19):1359-68. doi: 10.1056/NEJM199805073381906
2. Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity. 2011;44(5):373-83. doi: 10.3109/08916934.2011.541170
3. Krishnan MR, Wang C, Marion TN. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Kidney Int. 2012;82(2):184-92. doi: 10.1038/kli.2011.484
4. Starke C, Frey S, Wellmann U, Urbonaviciute V, Herrmann M, Amann K, et al. High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Eur J Immunol. 2011;41(7):2107-12. doi: 10.1002/eji.201041315.
5. Chang A, Henderson SG, Brandt D, Liu N, Guttkiadora R, Hsieh C, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011;186(3):1849-60. doi: 10.4049/jimmunol.1001983
6. Dall’Era M, Stone D, Levesque V, Cistermans M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res. 2011;63(3):351-7. doi: 10.1002/acr.20397.
7. Ayodele OE, Olpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology. 2010;15(4):482-90. doi: 10.1111/j.1440-1797.2010.01290.x.
8. Hiramatsu N, Kuroiwa T, Ikeuchi H, Maeshima A, Kaneko Y, Hiromura K, et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology. 2008;47(5):702-7. doi: 10.1093/rheumatology/ken191.
9. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14(11):890-5. doi: 10.1191/0961203305lu2238oa.
10. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. 2004;50(8):2559-68. doi: 10.1002/art.20364.
11. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000;35(5):904-14. doi: 10.1016/s027-6386(00)70262-9.
12. WB, Khan HN, Jovanovic B, Londono-Jimenez A, Izmirly P, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Semin Arthritis Rheum. 2018;47:545–51. doi: 10.1016/j.semarthrit.2017.07.007.
13. Yap DY, Yung S, Zhang Q, Tang C, Chan TM. Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis. Lupus. 2016;25(1):46-53. doi: 10.1177/0961203315598018.
14. Bonanni A, Vaglio A, Bruschi M, Sinico RA, Cavagna L, Moroni G, et al. Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference. Autoimmun Rev. 2015;14(8):692-702. doi: 10.1016/j.autrev.2015.04.004.
15. Ronda N, Cravedi P, Benozzi L, Lughli P, Bonati A, Allegri L, et al. Early proinflammatory activation of renal tubular cells by normal and pathologic IgG. Nephron Exp Nephrol. 2005;100(2):c77-8. doi: 10.1159/000084573.
16. Celé JW, Rutjes NW, Keuning ED, Soinen R, Heljasvaara R, Pihlajaniemi T, et al. Subendothelial heparan sulfate proteoglycans become major L-selectin and monocyte chemoattractant protein-1 ligands upon renal ischemia/reperfusion. Am J Pathol. 2007;170(6):1865-78. doi: 10.2353/ajpath.2007.070061.
17. Celé JW, Reijmers RM, Slot EM, Beelen RH, Spatarogen M, ter Wei PM, et al. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol. 2008;294(1):F253-63. doi: 10.1152/ajprenal.00429.2007.
18. Alexopoulou AN, Multhaupt HA, Couchman JR. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol. 2007;39(3):505-28. doi: 10.1016/j.biocel.2006.10.014.
19. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006;6(9):633-43. doi: 10.1038/nri1918.
20. Whitelock JM, Iozzo RV. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev. 2005;105(7):2745-64. doi: 10.1021/cr010213m.
21. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435-71. doi: 10.1146/annurev.biochem.71.110601.135458.
22. Wang L, Fuster M, Srimarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 2005;6(9):902-10. doi: 10.1038/ni1233.
23. Stepp MA, Gibson HE, Gala PH, Iglesia DD, Pajoohesh-Ganji A, Pal-Ghosh S, et al. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J Cell Sci. 2002;115(23):4517-31. doi: 10.1242/jcs.00128.
24. Kato M, Saunders S, Nguyen H, Bernfield M. Loss of
cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell. 1995;6(5):559-76. doi: 10.1091/mbc.6.5.559.

25. Vainio S, Lehtonen E, Jalkanen M, Bernfield M, Saxén L. Epithelial-mesenchymal interactions regulate the stage-specific expression of a cell surface proteoglycan, syndecan, in the developing kidney. Dev Biol. 1989;134(2):382-91. doi: 10.1016/0012-1606(89)90110-3.

26. Subramanian SV, Fitzgerald ML, Bernfield M. Regulated shedding of syndecan-1 and-4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272(23):14713-20. doi: 10.1074/jbc.272.23.14713.

27. Steppan J, Hofer S, Funke B, Brenner T, Henrich M, Martin E, et al. Sepsis and major abdominal surgery lead to flaking of the endothelial glyocalyx. J Surg Res. 2011;165(1):136-41. doi: 10.1016/j.jss.2009.04.034.

28. Seidel C, Ringdén O, Remberger M. Increased levels of syndecan-1 in serum during acute graft-versus-host disease. Transplantation. 2003;76(2):423-6. doi: 10.1097/01.TP0000074316.76104.A5.

29. Seidel C, Sundan A, Hjorth M, Tioussen I, Dahl IMS, Abildgaard N, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2006;95(2):388-92. doi: 10.1182/blood.V95.2.388.

30. Larsen AM, Leinece EB, Johansson PL, Birgens H, Ostrowski SR. High syndecan-1 levels in acute myeloid leukemia are associated with bleeding, thrombocytopenia, endothelial cell damage, and leukocytosis. Leuk Res. 2013;37(7):777-83. doi: 10.1016/j.leukres.2013.02.015.

31. Fajardo-Robledo NS, Díaz-Rizo V, Perez-Guerrero EE, Bonilla-Lara D, Saldaña-Angiunio JM, Munoz-Valle JE, et al. FRI0416 Syndecan-1 (CD138), B lymphocyte stimulator (BLYS) and their association with clinical variables and autoantibodies in systemic lupus erythematosus. Ann Rheum Dis. 2015;74(Suppl 2):S77.

32. Salam RF, Khalim NA, Alnaggar AR, Mohamady O, Maher A, Rashid LA. Role of syndecan-1 (CD138) in Egyptian systemic lupus erythematosus patients with lupus nephritis: Relation to disease activity. Egypt. Rheumatol. 2019;41(4):276-84.

33. Rops AL, Götte M, Baselmans MH, Van Den Hoven MJ, Steenenbergen EJ, Lensen JF, et al. Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int. 2007;72(10):1204-15. doi: 10.1038/sj.ki.5002514.

34. Kim KJ, Kim JY, Baek JW, Kim WU, Cho CS. Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus. J Rheumatol. 2015;42(2):202-9. doi: 10.3899/jrheum.140568.

35. Zhang Y, Wang Z, Liu J, Zhang Z, Chen Y. Suppressing syndecan-1 shedding ameliorates intestinal epithelial inflammation through inhibiting NF-kB pathway and TNF-α. Gastroenterol Res Pract. 2016;2016:6421351. doi: 10.1155/2016/6421351.

36. Pamfil C, Makowska Z, De Groof A, Tilman G, Babsa S, Galant C, et al. Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis. Ann Rheum Dis. 2018;77(12):1782-9. doi: 10.1136/annrheumdis-2018-213485.

37. Espeli M, Biders S, Giannico G, Dickinson HA, Barsley V, Fogo AB, et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol. 2011;22(2):296-305. doi: 10.1681/ASN.2010050515.

38. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50. doi: 10.1097/01.asn.0000108969.21691.5d.

39. Austin HR, Muenz LR, Joyce KM, Antonoych T, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med. 1983;75(3):382-91. doi: 10.1016/0002-9343(83)90338-8.

40. Austin HA, Muenz LR, Joyce KM, Antonoych T, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25(4):689-95. doi: 10.1007/ki.1984.75.

41. Celie JW, Katka KK, Adepu S, Melenhorst WB, Reijmers RM, Slot EM, et al. Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation. Kidney Int. 2012;81(7):651-61. doi: 10.1038/ki.2011.425.

42. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992;8:365-93. doi: 10.1146/annurev.cb.08.110192.002053.

43. Roskams T, Moshage H, De Vos R, Guido D, Yap P, Desmet V. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995;21(4):950-8. doi: 10.1002/hep.1840210410.

44. Adepu S, Rosman CW, Dam W, van Dijk MC, Navis G, van Goor H, et al. Incipient renal transplant dysfunction associates with tubular syndecan-1 expression and shedding. Am J Physiol Renal Physiol. 2015;309(2):F137-45. doi: 10.1152/ajprenal.00127.2015.

45. Sanderson RD, Lalar P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989;1(1):27-35. doi: 10.1091/mbc.1.1.27.

46. Minowa K, Amano H, Nakano S, Ando S, Watanabe T, Nakiri Y, et al. Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus. Autoimmunity. 2011;44(5):357-62. doi: 10.3109/08916934.2010.545846.

47. Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int. 2010;77(9):820-9. doi: 10.1038/ki.2010.13.